Evidence map›Paper›PMID 37834203›Full record

ReviewInternational journal of molecular sciences2023

Interaction of the Gut Microbiome and Immunity in Multiple Sclerosis: Impact of Diet and Immune Therapy.

Sudhir Kumar Yadav, Kouichi Ito, Suhayl Dhib-Jalbut

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Gut-brain axis in health and brain disease.Chinese medical journal · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Multiple sclerosis: molecular pathogenesis and therapeutic intervention.Signal transduction and targeted therapy · 2025
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. CD8Frontiers in immunology · 2025
    Article
  18. Review
  19. Review
  20. The Lreu_1276 protein fromApplied and environmental microbiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sudhir Kumar YadavDepartment of Neurology, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.
Kouichi ItoDepartment of Neurology, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.
Suhayl Dhib-JalbutDepartment of Neurology, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.
Johnson University · US

Funding

National Multiple Sclerosis Society RG-1901-33077Ruth Dunietz Kushner and Michael Jay Serwitz endowed Chair Ruth Dunietz Kushner and Michael Jay Serwitz endowed Chair
6 · The paper itself

Abstract

The bidirectional communication between the gut and central nervous system (CNS) through microbiota is known as the microbiota-gut-brain axis. The brain, through the enteric neural innervation and the vagus nerve, influences the gut physiological activities (motility, mucin, and peptide secretion), as well as the development of the mucosal immune system. Conversely, the gut can influence the CNS via intestinal microbiota, its metabolites, and gut-homing immune cells. Growing evidence suggests that gut immunity is critically involved in gut-brain communication during health and diseases, including multiple sclerosis (MS). The gut microbiota can influence the development and function of gut immunity, and conversely, the innate and adaptive mucosal immunity can influence microbiota composition. Gut and systemic immunity, along with gut microbiota, are perturbed in MS. Diet and disease-modifying therapies (DMTs) can affect the composition of the gut microbial community, leading to changes in gut and peripheral immunity, which ultimately affects MS. A high-fat diet is highly associated with gut dysbiosis-mediated inflammation and intestinal permeability, while a high-fiber diet/short-chain fatty acids (SCFAs) can promote the development of Foxp3 Tregs and improvement in intestinal barrier function, which subsequently suppress CNS autoimmunity in the animal model of MS (experimental autoimmune encephalomyelitis or EAE). This review will address the role of gut immunity and its modulation by diet and DMTs via gut microbiota during MS pathophysiology.

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalGastrointestinal MicrobiomeMultiple SclerosisAnimalsCentral Nervous SystemDietDysbiosiscentral nervous system autoimmunitydietdisease-modifying therapiesgut immunitygut microbiotamultiple sclerosis

Identifiers

PMID37834203
PMCPMC10572709
OpenAlexW4387231383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.